Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28422712 | 0.79 | — | — | |
| SCHEMBL10936828 | 0.77 | — | — | |
| SCHEMBL8633462 | 0.77 | CYP1A2 (0.30) | — | |
| SCHEMBL28926494 | 0.75 | LMNA (0.36) | GAACA2ALDH1A1 | |
| SCHEMBL7431492 | 0.69 | TSHR (0.44) | GAACA1CA2CA9ALDH1A1 | |
| SCHEMBL17755155 | 0.67 | SLC6A4 (0.47) | ALDH1A1 | |
| SCHEMBL19088279 | 0.67 | GAA (0.42) | GAACA1CA2CA9ALDH1A1 | |
| SCHEMBL29581599 | 0.67 | SCN4A (0.37) | ALDH1A1 | |
| SCHEMBL27387343 | 0.67 | SCN4A (0.37) | ALDH1A1 | |
| SCHEMBL13639172 | 0.66 | SCN4A (0.48) | GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338562-A1 | METHODS FOR THE PREPARATION OF LINKER PAYLOAD CONSTRUCTS | SYNAFFIX B.V. (NL) | 2023-10-26 | — | — | US | disclosed |
| US-20230338562-A1 | METHODS FOR THE PREPARATION OF LINKER PAYLOAD CONSTRUCTS | SYNAFFIX B.V. (NL) | 2023-10-26 | — | — | US | disclosed |
| US-9678083-B2 | Protected amine labels and use in detecting analytes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338562-A1 | METHODS FOR THE PREPARATION OF LINKER PAYLOAD CONSTRUCTS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DRD3, SNRPD3 | GAA 3322/4885CA1 2684/4885CA2 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.